公司股价表现 - MoonLake Immunotherapeutics股价跌至624美元 跌幅达8993% [1][6] - KALA BIO股价跌至213美元 跌幅达8882% [2][6] - IO Biotech股价跌至035美元 跌幅达7731% [3][6] - Maris-Tech股价跌至022美元 跌幅达7116% [4] 公司特定事件 - MoonLake Immunotherapeutics面临律师事务所潜在索赔调查 [1] - KALA BIO停止特定眼病实验性治疗药物开发 [2] - IO Biotech遭FDA建议不基于IOB-013临床试验数据提交生物制剂许可申请 将进行重组并裁员约50% [3] - Maris-Tech作为数字音视频硬件软件解决方案提供商 可能受行业技术升级或竞争压力影响 [4] 行业特征 - 生物制药与技术行业公司出现显著股价波动 [5] - 市场情绪、行业趋势及公司特定发展是影响股价的关键因素 [5]

AnaptysBio (NasdaqGS:ANAB) Update / Briefing September 29, 2025 04:30 PM ET Company ParticipantsDaniel Faga - President, CEO & DirectorAnupam Rama - Executive Director - Biotechnology Equity ResearchAlex Thompson - Managing DirectorDennis Mulroy - CFOConference Call ParticipantsYatin Suneja - Senior MD & Equity Research Analyst - BiotechnologyJoseph Thome - MD & Senior Biotechnology Equity Research AnalystAndy Chen - Director & Senior Equity Research AnalystYasmeen Rahimi - MD & Senior Research AnalystDavid ...

Strategic Separation to Maximize Shareholder Value Sept. 29, 2025 Safe harbor statement This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company's clinical trials, including initial data for rosnilimab's Phase 2 clinical trial in ulcerative colitis; expectations regarding the structure ...

CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,733,766 shares of common stock at a purchase price of $1.30 per share, in a private placement to accredited investors and a Company director. Each share of common stock is being offered toge ...

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p.m. ET on Tu ...

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p.m. ET on Tu ...

Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced it has entered into a senior secured term loan facility of up to $250 million with an affiliate of RA Capital Management (RA Capital), the compan ...

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14. The event will include Joseph A. Murray, M.D., professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology at the Mayo Clinic, along ...

Cash runway extended through 2026 to fund multiple expected key inflection points  , /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the closing of its previously announced "reasonable best efforts" public offering with participation from existing and certain healthcare focused institutional investors for the pu ...

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatment retention in both VESPER-1 and VESPER-3 trials Data support Phase 3 initiation in late 2025 NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of VESPER-3 – two Phas ...